The Protein Tyrosine Kinase Inhibitor Nilotinib as First-line Treatment of Ph+ Chronic Myeloid Leucemia (CML) in Early Chronic Phase: a Phase II Exploratory, Multicenter Study. GIMEMA Protocol CML 0307. EUDRACT 2007-000597-22.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 05 Oct 2020 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Final results (ten year follow-up data) of this study, were released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 04 Dec 2018 Results comparing the prognostic value of ELTS and Sokal scores in a cohort of CML patients treated frontline with tyrosine kinase inhibitors presented at the 60th Annual Meeting and Exposition of the American Society of Hematology